Section Arrow
Quote
KLTO.NASDAQ
- Klotho Neurosciences Inc
(Financial Status)
Quotes are at least 15-min delayed:2025/07/14 16:15 EDT
After Hours
Last
 1.28
+0.03 (+2.40%)
Bid
1.28
Ask
1.3
High 1.31 
Low 1.25 
Volume 5439 
Regular Hours
Last
 1.25
-0.05 (-3.85%)
Day High 
1.3 
Prev. Close
1.3 
1-M High
2.45 
Volume 
3.63M 
Bid
1.28
Ask
1.3
Day Low
1.14 
Open
1.245 
1-M Low
0.6808 
Market Cap 
47.44M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.2 
20-SMA 1.35 
50-SMA 0.75 
52-W High 3.9099 
52-W Low 0.1135 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.27/--
Enterprise Value
47.44M
Balance Sheet
Book Value Per Share
0.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0459-0.0043-8.57%-- 
After Hours 0.0458 -0.0001 -0.22%
PMNProMIS Neurosciences0.52+0.129599+33.20%4.34PE
After Hours 0.4822 -0.0378 -7.27%
WINTWindtree Therapeutics Inc.0.79+0.06+8.22%0.84PE
After Hours 0.7945 +0.0045 +0.57%
DAREDare Bioscience Inc.3.09+0.575+22.86%0.1PE
After Hours 3.15 +0.06 +1.94%
RANIRani Therapeutics Holdings0.6984+0.0544+8.45%-- 
After Hours 0.6798 -0.0186 -2.66%
Quotes are at least 15-min delayed：2025/07/14 16:15 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drugportfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.